|Dr. Kevin C. Gorman||CEO & Director||1.38M||N/A||1958|
|Mr. Matthew C. Abernethy||Chief Financial Officer||781.04k||549.13k||1980|
|Mr. Kyle W. Gano||Chief Bus. Devel. and Strategy Officer||711.72k||N/A||1973|
|Mr. Eric S. Benevich||Chief Commercial Officer||748.83k||1.25M||1965|
|Dr. Eiry Wyn Roberts||Chief Medical Officer||847.94k||260.95k||1964|
|Dr. Dimitri E. Grigoriadis||Chief Research Officer||N/A||N/A||1958|
|Jane Sorensen||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Darin M. Lippoldt||Chief Legal Officer & Corp. Sec.||N/A||N/A||1966|
|Ms. Julie S. Cooke||Chief HR Officer||N/A||N/A||1966|
|Mr. Malcolm C. Lloyd-Smith||Chief Regulatory Officer||N/A||N/A||1956|
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 4; Compensation: 4.